VX-745 is a lead anti-inflammatory candidate, small-molecule inhibitor of mitogen-activated protein kinase (MAPK).VX-745 is potent against p38R (IC50=10 nM) and blocks TNFR production in LPS-stimulated HWB in vitro (IC50=177 nM). (1)